Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Investigational drug notice
Retatrutide is an investigational drug. It has not been approved by the FDA and is not legally available outside clinical trials. FormBlends does not sell, supply, prescribe, or facilitate access to retatrutide. This article discusses fatigue as reported in published phase 2 trial data and references comparable patterns from approved GLP-1 class medications.
Key Takeaways
- Retatrutide phase 2 reported fatigue in approximately 11-14% of patients on active doses; placebo arm reported around 6%
- Fatigue was generally mild to moderate, dose-dependent, and did not commonly cause discontinuation
- The pattern matches the GLP-1 class. Semaglutide STEP 1: ~11%. Tirzepatide SURMOUNT-1: ~7-8%
- Likely drivers include rapid caloric reduction, weight-loss-related metabolic adaptation, dehydration from nausea, and direct drug effects of unclear magnitude
- Most fatigue improves within 4-8 weeks. Persistent fatigue beyond 8-12 weeks should trigger evaluation for other causes
Direct answer
Yes, retatrutide caused fatigue in a meaningful minority of trial participants. The incidence was higher than placebo and increased with dose, but the magnitude was similar to other GLP-1 class drugs. Most cases were mild and resolved or improved with continued treatment. Severe or persistent fatigue beyond 8-12 weeks warrants workup for other contributing causes rather than blame on the drug alone.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What the phase 2 trial actually reported
- Comparison to GLP-1 class fatigue rates
- Why GLP-1 drugs make people tired
- The titration window: when fatigue is worst
- The protein-and-electrolytes management approach
- When fatigue is not the drug's fault
- The metabolic adaptation phenomenon
- Dose-by-dose pattern
- Sex and age differences
- The contrary view: maybe the fatigue is being underreported
- FAQ
- Sources
What the phase 2 trial actually reported
The retatrutide phase 2 obesity trial (Jastreboff et al., NEJM 2023) included fatigue among solicited treatment-emergent adverse events. The published data:
| Arm | Fatigue incidence over 48 weeks |
|---|---|
| Placebo | ~6% |
| 1 mg retatrutide | ~8% |
| 4 mg retatrutide | ~11% |
| 8 mg retatrutide | ~13% |
| 12 mg retatrutide | ~14% |
Most events were classified as mild (CTCAE grade 1) or moderate (grade 2). Grade 3 or higher severe fatigue was uncommon. Discontinuation attributed to fatigue specifically was rare. The placebo rate of 6% reflects that some fatigue in obesity trial populations comes from lifestyle modification, study burden, or unrelated medical issues, not drug effect.
The drug-attributable rate (active dose minus placebo) at 12 mg is therefore approximately 8 percentage points. That is the cleanest estimate of how much extra fatigue the drug specifically caused.
Comparison to GLP-1 class fatigue rates
| Drug | Trial | Fatigue at top dose | Placebo |
|---|---|---|---|
| Semaglutide 2.4 mg | STEP 1 | ~11% | ~5% |
| Tirzepatide 15 mg | SURMOUNT-1 | ~7-8% | ~4% |
| Liraglutide 3.0 mg | SCALE Obesity | ~7% | ~5% |
| Retatrutide 12 mg | Phase 2 | ~14% | ~6% |
Retatrutide's reported rate is at the upper end of the class but not dramatically out of range. Several confounders may explain the slight elevation: the smaller phase 2 sample size (338 patients total, ~60 per dose arm) means each percentage point is sensitive to a handful of cases. Phase 2 trials also tend to ask more detailed adverse event questions, which can elevate reported rates for symptoms like fatigue that are partially subjective.
Whether retatrutide produces genuinely more fatigue than tirzepatide will be clearer when phase 3 TRIUMPH data publishes with larger sample sizes and matched timepoints.
Why GLP-1 drugs make people tired
The mechanistic picture has several pieces, each contributing partially:
- Rapid caloric reduction. GLP-1 drugs suppress appetite. Many patients drop daily intake by 500-1,000 kcal during early titration. This caloric deficit is exactly what produces weight loss, but it also produces the energy-state effects associated with caloric restriction (lower thermogenesis, fatigue, mild irritability)
- Dehydration from nausea. Early-titration nausea reduces fluid intake. Mild dehydration is a common cause of fatigue and is often what patients are actually experiencing when they describe "feeling tired"
- Electrolyte shifts. Sodium intake often drops with reduced eating. Potassium and magnesium intake may also drop. These shifts produce fatigue, muscle cramping, and orthostatic symptoms
- Sleep disruption. Some patients on GLP-1 drugs report changes in sleep architecture, often related to nighttime nausea or gastroesophageal symptoms from slowed gastric emptying
- Central effects. GLP-1 receptor signaling occurs in the central nervous system. The clinical relevance of direct CNS effects on alertness is unclear. The glucagon component in retatrutide may add additional central effects, but specific data is limited
- Metabolic adaptation. As weight loss proceeds, resting metabolic rate drops, thyroid hormone levels often shift downward (T3 reduction is a classic adaptation), and leptin signaling changes. These adaptations produce a low-energy state that takes weeks to months to stabilize
The titration window: when fatigue is worst
Across the GLP-1 class, the worst fatigue typically occurs in weeks 2-8 of treatment, coinciding with rapid dose escalation. The pattern usually looks like:
- Week 1: minimal fatigue, treatment effects still mild
- Week 2-4: nausea and fatigue intensify as the body adjusts to caloric reduction
- Week 4-8: fatigue often peaks, especially after a dose increase
- Week 8-12: most patients adapt; fatigue improves substantially
- Beyond week 12: residual fatigue is usually mild and stable
For retatrutide specifically, phase 2 used a slower titration than is sometimes seen in practice with other drugs. The protocol stepped patients up gradually (4-week intervals), which likely produced milder fatigue at any given dose change than a faster titration would have.
The protein-and-electrolytes management approach
Clinical management of GLP-1 fatigue follows a consistent pattern across approved drugs and would likely apply to retatrutide once available:
- Protein. Aim for 1.2-1.6 g/kg of goal body weight per day. For a 175 lb (79 kg) goal weight, this is roughly 95-127 g of protein daily. Adequate protein supports muscle preservation during weight loss and helps stabilize blood sugar through the day
- Electrolytes. Add salt to meals. Consider an electrolyte supplement (sodium, potassium, magnesium) if reduced food intake is producing low overall intake. Electrolyte sticks or unsweetened versions of sports drinks work for many patients
- Hydration. Aim for clear urine. Many patients underdrink because they no longer feel thirsty or because nausea limits sipping. Set a target of 64-96 oz of water daily
- Caloric floor. Even on a weight-loss regimen, most adults should not drop below 1,200-1,400 kcal sustained. Lower intakes cause more fatigue, more muscle loss, and rarely produce better long-term results
- Sleep. Prioritize 7-9 hours nightly. Sleep deprivation amplifies fatigue and increases appetite signals that may undermine the drug's effect
- Exercise. Light to moderate exercise (walking, gentle resistance training) usually improves rather than worsens fatigue. Heavy training during titration often does the opposite. Match exercise intensity to current energy state
When fatigue is not the drug's fault
Persistent fatigue beyond 8-12 weeks of stable dosing is more likely related to something other than the drug itself. Workup considerations:
- Anemia. CBC. Iron deficiency anemia is common, especially in women of reproductive age, and produces classic fatigue
- Thyroid. TSH and free T4. Weight loss can shift thyroid function. Subclinical hypothyroidism may emerge or worsen
- Vitamin D. Levels below 20 ng/mL are associated with fatigue. Levels below 30 ng/mL are often supplemented
- B12. Especially in patients on metformin or with reduced animal protein intake
- Depression. Mood symptoms can present primarily as fatigue. Some patients on GLP-1 drugs experience changes in mood that warrant attention
- Sleep apnea. Often comorbid with obesity. Weight loss can improve apnea but may unmask previously compensated cases. Daytime fatigue with snoring or witnessed apneas should trigger sleep study consideration
- Underlying chronic disease. Diabetes (if poorly controlled), liver disease, kidney disease, or other systemic conditions can all produce fatigue independent of medication
The metabolic adaptation phenomenon
One reason fatigue persists in some patients well past the titration window is metabolic adaptation. As body weight drops, resting energy expenditure drops more than would be predicted by simple body-composition math. The pattern was documented dramatically in the Biggest Loser follow-up study (Fothergill et al., Obesity 2016), where contestants had resting metabolic rates 500 kcal/day below predicted years after weight loss.
Incretin drugs may partially blunt this adaptation by improving leptin signaling and reducing the hunger-driven counter-regulatory response that sabotages many weight-loss attempts. But they do not fully eliminate metabolic adaptation. Patients losing meaningful amounts of weight will experience some metabolic slowdown, which contributes to fatigue and to the difficulty of losing additional weight beyond a maintenance plateau.
The glucagon component in retatrutide is theoretically protective here: glucagon receptor activation increases resting energy expenditure, which should counter metabolic adaptation. Whether this translates to less fatigue during weight loss is an open question. Phase 3 will provide more data.
Dose-by-dose pattern
The dose-dependent fatigue pattern in phase 2 tracked roughly with the weight-loss pattern. Higher doses produced more weight loss and more fatigue. The 8 mg arm showed weight loss almost as large as 12 mg (22.8% vs 24.2%) with slightly less fatigue, which suggests 8 mg may be a practical sweet spot for many patients when the drug becomes available. The labeled maintenance doses after approval will depend on phase 3 readouts.
Sex and age differences
The phase 2 sample size was too small to draw strong conclusions about subgroup differences. Across the GLP-1 class generally, women report slightly more fatigue and gastrointestinal symptoms than men, often attributed to body composition and dosing differences. Older adults (over 65) report more fatigue with rapid weight loss, often related to comorbidities and concurrent medications rather than direct drug effects.
A patient's individual response is more important than population averages. Some patients tolerate full doses with minimal fatigue; others struggle even at low doses. Clinical management is individualized.
The contrary view: maybe the fatigue is being underreported
Trial-reported adverse event rates are often lower than real-world rates for several reasons. Patients in trials are pre-screened for high adherence and tolerance. Reporting fatigue requires patients to characterize a subjective symptom against ill-defined thresholds. Some patients underreport to avoid being asked to drop out. Some clinicians under-record minor complaints in case report forms.
Real-world experience with semaglutide and tirzepatide post-approval has shown fatigue, energy changes, and "feeling off" reports running higher than trial data predicted. The same pattern is likely for retatrutide after approval and post-marketing surveillance. Trial data is a floor estimate, not a ceiling.
Implication for patient counseling: the published 14% figure should be communicated as "at least this many patients experienced fatigue in the trial, with real-world rates probably somewhat higher." Setting expectations at the higher end reduces surprise and improves adherence.
FAQ
How long does retatrutide fatigue last? Most patients see improvement within 4-8 weeks. Some have lingering mild fatigue throughout treatment that they tolerate.
Can I take caffeine while on retatrutide? Caffeine is fine for most patients. Some experience increased anxiety or heart rate sensitivity during rapid titration; tapering caffeine intake during this window can help.
Should I exercise if I feel tired on the drug? Light to moderate exercise usually helps. Avoid heavy training during the steepest titration weeks if energy is low.
Is fatigue worse than other GLP-1 drugs? Cross-trial comparison suggests retatrutide's fatigue rate is in the same general range as semaglutide and slightly higher than tirzepatide. Head-to-head data does not exist.
Will I be tired forever on this drug? No. Most patients reach a stable energy state after the titration window. Maintenance-dose fatigue, if present, is usually mild.
Does drinking more water help? Often yes. Mild dehydration is a common contributor to fatigue in this population.
What if I am too tired to function? Severe fatigue is unusual and warrants medical evaluation. Other causes (anemia, thyroid, depression, sleep apnea) should be ruled out. Dose reduction or pause may be appropriate while workup proceeds.
Does retatrutide cause brain fog? Some patients report cognitive sluggishness during rapid weight loss across the GLP-1 class. The drug-specific contribution is unclear. Hydration, electrolytes, and adequate protein usually help.
Can I take iron or B12 with retatrutide? Yes. Routine supplementation is fine and is often recommended during weight loss to protect against deficiency-related fatigue.
Sources
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity). New England Journal of Medicine. 2015.
- Fothergill E et al. Persistent Metabolic Adaptation 6 Years After "The Biggest Loser" Competition. Obesity. 2016;24:1612-1619.
- Rosenstock J et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023;402:529-540.
- Rosenbaum M, Leibel RL. Adaptive Thermogenesis in Humans. International Journal of Obesity. 2010.
- Endocrine Society Clinical Practice Guideline on Pharmacological Management of Obesity, 2024 Update.
- FDA. Wegovy (semaglutide) Prescribing Information.
- FDA. Zepbound (tirzepatide) Prescribing Information.
- American Association of Clinical Endocrinologists. Comprehensive Medical Care Guidelines for Patients with Obesity, 2024 Update.
Footer disclaimers
Platform Disclaimer. FormBlends is a telehealth platform that matches patients with independent licensed providers and U.S.-based pharmacies. We do not prescribe, manufacture, or dispense medication directly. Treatment plans, dose adjustments, and adverse event management are clinical decisions made by the prescribing provider.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are produced by state-licensed 503A compounding pharmacies in response to individual prescriptions. They are not FDA-approved and are not interchangeable with brand-name products.
Investigational Drug Notice. Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or facilitate access to retatrutide. Adverse event data referenced on this page comes from published phase 2 trial results.
Results Disclaimer. Adverse event rates reflect study-population averages. Individual experience with side effects, including fatigue, varies based on titration speed, individual sensitivity, concurrent medications, and underlying health status.
Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.